|
SRGAP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.77891035235689E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.54858373188927E-13 |
| Normal-vs-Stage2 |
7.998800E-03 |
| Normal-vs-Stage3 |
4.9553999792451E-09 |
| Normal-vs-Stage4 |
1.41499999495309E-08 |
| Stage1-vs-Stage2 |
1.900440E-02 |
| Stage1-vs-Stage3 |
7.243400E-01 |
| Stage1-vs-Stage4 |
2.488600E-01 |
| Stage2-vs-Stage3 |
4.824400E-02 |
| Stage2-vs-Stage4 |
4.495100E-03 |
| Stage3-vs-Stage4 |
1.869030E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.65456537359887E-12 |
| Normal-vs-AfricanAmerican |
5.786600E-04 |
| Normal-vs-Asian |
3.16509999986891E-07 |
| Caucasian-vs-AfricanAmerican |
3.016600E-01 |
| Caucasian-vs-Asian |
3.089800E-01 |
| AfricanAmerican-vs-Asian |
2.205200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.73849999951514E-08 |
| Normal-vs-Female |
7.92699239582362E-14 |
| Male-vs-Female |
2.498600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.14217532601424E-12 |
| Normal-vs-Age(41-60Yrs) |
4.03890254574435E-11 |
| Normal-vs-Age(61-80Yrs) |
1.85984999999667E-05 |
| Normal-vs-Age(81-100Yrs) |
3.544300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.678830E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.894220E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.351200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.691640E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.770200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.082400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.397800E-01 |
| Classical-VS-Follicular |
1.65234492754962E-12 |
| Classical-VS-Other |
8.565600E-02 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
1.64901999999412E-05 |
| Tall-VS-Other |
6.118000E-02 |
| Tall-VS-Normal |
5.91070004052341E-09 |
| Follicular-VS-Other |
5.236800E-01 |
| Follicular-VS-Normal |
1.816570E-01 |
| Other-VS-Normal |
1.369760E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.61979999968587E-07 |
| Normal-vs-N1 |
1.61380000474054E-08 |
| N0-vs-N1 |
5.966300E-02 |
|
|
